AlphaStocks

AZN vs EXPO

ASTRAZENECA PLC vs EXPONENT INC — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

EXPO

EXPONENT INC

4.6

Weak

$65.07

AZN vs EXPO: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while EXPONENT INC (EXPO) scores 4.6/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, ASTRAZENECA PLC trades at 30.4x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNEXPO
Scores & Fundamentals
Composite Score8.4/104.6/10
RatingStrong BuyWeak
Price$200.99$65.07
P/E Ratio30.431.4
ROE21.9%16.0%
Market Cap$312B$3B
Fair Value$192.63$54.68
Dividend Yield1.6%1.9%
Sector Rank#3 of 1127#690 of 1127
Model Verdicts
PiotroskiStrongAttractive
BuffettStrongAttractive
GrahamCautionNeutral
LynchNeutralNeutral
GreenblattNeutralLimited Data
View full AZNanalysis →View full EXPOanalysis →
Compare any two stocks →

AZN vs EXPO: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and EXPONENT INC (EXPO) are among the most compared stocks in the S&P 500. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to EXPO's 4.6/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer